Prospective investigator-initiated study for 2 years’ follow-up of Episealer® Talus patients initiated
Episurf Medical (Nasdaq: EPIS B) today announces the initiation of a prospective investigator-initiated study with 2 years’ follow-up of 25 Episealer® Talus patients. The study is performed by a team at Royal National Orthopaedic Hospital NHS Trust, Stanmore, United Kingdom, with Mr Karan Malhotra as Principal Investigator. The Royal National Orthopaedic Hospital is the largest orthopaedic hospital in the UK, and regarded as a leader in the field of orthopaedics both in the UK and world-wide. The study will evaluate the clinical performance of the Episealer® Talus implant in patients who undergo surgical treatment with the implant at the hospital. Episealer® Talus is Episurf Medical’s CE marked joint implant intended for treatment of osteochondral ankle lesions.
“We are grateful that the Royal National Orthopaedic Hospital has initiated this study. Clinical evidence is of highest importance for us while we are also focusing on entering new markets. The fact that this reputable hospital decided to perform this study, confirms to us the genuine interest in UK for our technology” says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
Email: pal.ryfors@episurf.com
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical’s Episealer® individualised implants and Epiguide® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 15.30 CEST on 7 April 2022.
Tags: